Get started
Author

Francis Ayuketang Ayuk

Observed names: Ayuk, F, Ayuk, F., Ayuk, Francis, Ayuk, Francis Ayuketang, F A Ayuk, F Ayuk, F. A. Ayuk, F. Ayuk, Francis A Ayuk, Francis A. Ayuk, Francis Ayuk
Observed institutions: Universität Hamburg, Sheba Medical Center, Deutsche Klinik für Diagnostik, Assistance Publique – Hôpitaux de Paris, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Jena University Hospital, Hôpital Saint-Louis, Friedrich Schiller University Jena
ORCID: 0000-0001-6297-1847
Observed ORCID: 0000-0001-6297-1847
OpenAlex ID: A5082862253
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
2015 · Andrew C. Harris, Rachel Young, et al. · Transplantation and Cellular Therapy · 1,015
PDF
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease
2016 · Nicolaus Kröger, Carlos Solano, et al. · New England Journal of Medicine · 573
PDF
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
2015 · R Zeiser, A Burchert, et al. · Leukemia · 539
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
2021 · Kai Rejeski, Ariel Perez, et al. · Blood · 475
PDF
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease
2010 · Daniel Wolff, Michael Schleuning, et al. · Transplantation and Cellular Therapy · 327
PDF
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
2018 · Nimitha R Mathew, Francis Baumgartner, et al. · Nature Medicine · 295
Consensus Conference on Clinical Practice in Chronic Graft-versus-Host Disease (GVHD): First-Line and Topical Treatment of Chronic GVHD
2010 · Daniel Wolff, Armin Gerbitz, et al. · Transplantation and Cellular Therapy · 246
PDF
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
2017 · Matthew J. Hartwell, Umut Özbek, et al. · JCI Insight · 225
PDF
Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation
2018 · Mareike Frick, Willy Chan, et al. · Journal of Clinical Oncology · 223
GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
2022 · Wolfgang Andreas Bethge, Peter Martus, et al. · Blood · 214
PDF
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
2018 · Hannah Major-Monfried, Anne S. Renteria, et al. · Blood · 213
PDF
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
2018 · Matthew J. Hartwell, Umut Özbek, et al. · JCI Insight · 202
PDF
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
2024 · Felix Fischbach, Johanna Richter, et al. · Med · 192
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality
2002 · Nicolaus Kröger, Herbert Gottfried Sayer, et al. · Blood · 185
PDF
Pilot study of reduced‐intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis
2005 · Nicolaus Kröger, Tatjana Zabelina, et al. · British Journal of Haematology · 125
PDF
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR‐ligand mismatch after dose‐reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma
2005 · Nicolaus Kröger, Bronwen Shaw, et al. · British Journal of Haematology · 117
PDF
HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients
2018 · Dirk Westhölter, Jens Hiller, et al. · Journal of Hepatology · 115
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
2004 · Nicolaus Kröger, Avichai Shimoni, et al. · Blood · 112
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
2019 · Hrishikesh K. Srinagesh, Umut Özbek, et al. · Blood Advances · 111
PDF
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis
2023 · Caron A. Jacobson, Javier Munoz, et al. · Transplantation and Cellular Therapy · 109
Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans
2020 · Johana Norona, Petya Apostolova, et al. · Blood · 107
PDF
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
2017 · Nicolaus Kröger, Victoria Panagiota, et al. · Transplantation and Cellular Therapy · 106
PDF
JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
2014 · T Stübig, H Alchalby, et al. · Leukemia · 106
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells
2009 · M Lioznov, J El-Cheikh, et al. · Bone Marrow Transplantation · 103
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma
2004 · Nicolaus Kröger, Jose A. Perez-Simon, et al. · Transplantation and Cellular Therapy · 103
PDF
Works count: 408
Citation count: 12,150
H-index: 57
I10-index: 176
Year
Topic
Type